Subject characteristics
Characteristic . | IL-2+ART . | ART alone . | Untreated . |
|---|---|---|---|
| No. subjects | 10 | 11 | 11 |
| Initial HIV-1 RNA, median (range), log10 copies/mL | 4.9 (4.3-5.7) | 5.8 (5.3-6.2) | 4.9 (4.2-5.5) |
| Initial CD4+ T cells, median (range), cells/μL | 483 (324-638) | 452 (255-519) | 499 (376-593) |
| Male, % | 90 | 100 | 87 |
| Age, median (range), y | 34 (26-56) | 36 (24-47) | 37 (34-50) |
| Median estimated time from infection to treatment, d | 91 | 86 | NA |
| Preseroconversion at enrollment, % | 20 | 45 | 9 |
| PI-containing ART regimen, % | 40 | 64 | NA |
Characteristic . | IL-2+ART . | ART alone . | Untreated . |
|---|---|---|---|
| No. subjects | 10 | 11 | 11 |
| Initial HIV-1 RNA, median (range), log10 copies/mL | 4.9 (4.3-5.7) | 5.8 (5.3-6.2) | 4.9 (4.2-5.5) |
| Initial CD4+ T cells, median (range), cells/μL | 483 (324-638) | 452 (255-519) | 499 (376-593) |
| Male, % | 90 | 100 | 87 |
| Age, median (range), y | 34 (26-56) | 36 (24-47) | 37 (34-50) |
| Median estimated time from infection to treatment, d | 91 | 86 | NA |
| Preseroconversion at enrollment, % | 20 | 45 | 9 |
| PI-containing ART regimen, % | 40 | 64 | NA |
Comparisons across groups and pairwise comparisons between treated and untreated groups all P > .1.
NA indicates not applicable.